iRhythm Holdings (IRTC) Could Be 34% Undervalued Following Its Recent Rebound
iRhythm Holdings (IRTC) is back on investor radars after recent trading, with the stock closing at US$117.37. The move comes against a backdrop of mixed short and longer term share price performance.
See our latest analysis for iRhythm Holdings.
The strong 1 day share price return of 4.65% and 7 day share price return of 7.68% come after a weaker run, with the year to date share price return down 33.02% and the 1 year total shareholder return down 14.18%. However, the 5 year total shareholder return of 129.69% shows iRhythm Holdings has rewarded longer term holders.
If you are looking beyond iRhythm Holdings for other ideas in healthcare technology, this could be a useful moment to review 40 healthcare AI stocks.
After the latest rebound to US$117.37, iRhythm Holdings now trades well below both analyst targets and one intrinsic value estimate. Is that discount a genuine margin of safety, or is it a signal the market sees more risk ahead?
Most Popular Narrative: 34.4% Undervalued
The most followed narrative values iRhythm Holdings at $178.93 per share, compared with the latest close at $117.37. That gap sits at the center of a detailed set of growth and profitability assumptions.
Investment in the Zio ecosystem, including next-generation patches, enhanced form factors, and AI-powered analytics (such as the Lucem Health partnership), is improving product differentiation, diagnostic yield, and workflow efficiency, likely leading to higher gross margins and operating leverage as software and data become a larger component of the business.
Curious what kind of revenue ramp, margin lift, and earnings profile need to line up to support that $178.93 figure. The most influential assumptions sit in the growth rate, profitability path, and future earnings multiple. Those inputs are all laid out in the full narrative, but only if you are ready to see how much conviction sits behind this fair value call.
Result: Fair Value of $178.93 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the iRhythm Holdings story also hinges on resolving regulatory issues and keeping profitability on track, since setbacks here could quickly challenge that 34.4% undervaluation case.
Find out about the key risks to this iRhythm Holdings narrative.
Another View on iRhythm Holdings Valuation
The first narrative leans on earnings forecasts and a rich future P/E to argue that iRhythm Holdings looks undervalued. A different read comes from the current P/S ratio of 4.9x, which sits above both the US Medical Equipment industry at 2.8x and peers at 4.2x, and also above a fair ratio estimate of 4.3x. That higher multiple points to less room for error in the story if growth or margins fall short.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals around iRhythm Holdings can be confusing, so it helps to look at the full set of data and sentiment yourself and move quickly while the story is fresh. To see how current concerns and potential upsides balance out for this stock, review the 4 key rewards and 1 important warning sign
Looking for more investment ideas beyond iRhythm Holdings?
If you stop with iRhythm Holdings, you could miss other opportunities that better match your goals. Use the Simply Wall St screener to compare and pressure test alternatives.
- Target rock solid balance sheets and steady fundamentals by checking companies in the solid balance sheet and fundamentals stocks screener (48 results).
- Hunt for potential mispricing by reviewing candidates in the 49 high quality undervalued stocks.
- Spot lesser known opportunities with strong numbers by scanning the screener containing 20 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com